Neuvasq Biotechnologies
PrivateLast Round
Series A
Jun 22, 2021
Total Funding Raised
$23.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neuvasq Biotechnologies operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a Series A round in June 2021.
Neuvasq Biotechnologies is a biotechnology company that develops multispecific antibody-based therapies to restore and protect the integrity of the blood-brain and blood-retina barriers for the treatment of neurological and ophthalmic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuvasq Biotechnologies Comparables
Compare Neuvasq Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merck & Co., Inc. | 79% | |
| Lys Therapeutics | 78% | |
| Surrozen | 74% |
For institutional investors. Book with your work email.
Neuvasq Biotechnologies Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Neuvasq Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A |
| Newton Biocapital | Series A |
| Wallonie Entreprendre | Series A |
| ORSA | Series A |
| Sambrinvest | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 79% MoM.
- Apr 16, 2026
Monthly visitors increased 2700% MoM.
For institutional investors. Book with your work email.
Neuvasq Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neuvasq Biotechnologies's valuation, stock price, and market status.
Is Neuvasq Biotechnologies a public or private company?
Neuvasq Biotechnologies is a private company.
What is the current stock price of Neuvasq Biotechnologies?
Neuvasq Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Neuvasq Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuvasq Biotechnologies worth (valuation)?
Valuation information for Neuvasq Biotechnologies is not publicly available.
Can I buy Neuvasq Biotechnologies stock?
Neuvasq Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuvasq Biotechnologies's last funding round?
Neuvasq Biotechnologies's most recent funding round was Series A on June 22, 2021.
Who are the main investors in Neuvasq Biotechnologies?
Key investors in Neuvasq Biotechnologies include Newton Biocapital.
Will Neuvasq Biotechnologies IPO soon?
No public IPO plans have been announced for Neuvasq Biotechnologies.
How can I track Neuvasq Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Neuvasq Biotechnologies's shares on secondary markets.